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Editorial on the Research Topic
Vitamin C in Cancer and Infectious Diseases: Physiological, Biochemical and
Therapeutic Interventions
Vitamin C, also known as ascorbic acid, is an essential micronutrient in the human body.
Vitamin C is a co-factor for at least 15 enzymes involved in the biosynthesis of collagen and L-
carnitine, Hypoxia-Inducible Factor (HIF) degradation, peptide amidation, tyrosine metabolism,
and the conversion of dopamine to norepinephrine (Institute of Medicine (US) Panel on Dietary
Antioxidants Related Compounds, 2000; Pei et al., 2019). It is also a detoxifier and powerful
anti-oxidant, eliminating free radicals. Vitamin C is also a key regulator of immune function,
cellular growth and differentiation (Ang et al., 2018). Most animals are able to synthesize
vitamin C; however, 30–50 million ago humans lost the ability to synthesize the vitamin due
to the development of mutations in the gulonolactone oxidase gene (Drouin et al., 2011).
High concentrations of vitamin C act as a pro-oxidant, eliciting hydrogen peroxide–dependent
cytotoxicity in cancer cells without adversely affecting normal cells (Chen et al., 2008). High-
dose vitamin C has also been investigated in people and shown to improve the health-related
quality of life of terminal cancer and infectious diseases patients (Mikirova and Hunninghake,
2014). In this research topic, we have gathered together 7 articles; 2 original research contributions
and 5 review articles which are focused on the physiological role of vitamin C in health, the
biochemical and molecular mechanisms of vitamin C in cancer, and the importance of vitamin
C in infectious diseases.
Whether vitamin C has anti-cancer properties or not has been debated for decades (Cameron
and Pauling, 1978; Moertel et al., 1985; Nauman et al., 2018). The review by Vissers and
Das highlights the fact that vitamin C has been used for many years by cancer patients
in an unregulated environment, either as a dietary supplement or in pharmacological doses
administered by infusion. Daily vitamin C supplementation can likely reduce the incidence
of gastric, esophageal, oral, pharyngeal and cervical cancer, and vitamin C-rich fruits may
help prevent colon cancer and lung cancer (Pal et al., 2012). In addition, numerous reports
have shown when high-doses of vitamin C are combined with conventional chemotherapy
drugs the vitamin enhances the inhibition of cancer cell growth. Interestingly, the review by
Vissers and Das shows pharmacologic doses of vitamin C result in oxidative stress, which
preferentially targets cancer cells. Other mechanisms of action include vitamin C induced release
of mitochondrial cytochrome C, leading to H2O2-mediated activation of the caspase cascade and
apoptosis, and a significant decrease in tumor growth rates (Pei et al., 2016). Significant quantities
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of hydrogen peroxide are also generated by the autoxidation
of pharmacologic levels of vitamin C and stimulation of the
2-oxoglutarate dependent dioxygenase family of enzymes (2-
OGDDs) that require vitamin C as a cofactor. Support for
these proposed mechanisms has come from many in vitro
studies and xenograft animal models. With a number of
early phase clinical trials currently underway, evidence for
potential mechanisms of action is required to inform the most
appropriate study design and choice of cancer model. Park
et al. also reviewed the molecular mechanisms underlying
the regulation of oxidation/reduction systems, focusing on the
altered metabolomic profile in cancer cells. They suggested
vitamin C alters de novo synthesis of GSH, resulting in alterations
in the ratio of glutathione (GSH/GSSG). Alterations in GSH
metabolism is further associated with increased glutathionylation
of GAPDH, altered glucose metabolism, and high ROS levels
and GSH oxidation. We believe the scope of this research
topic provides the reader with insights into the multiple
molecular mechanisms responsible for the anti-cancer properties
of vitamin C.
In the present research topic, Carr and Cook investigated the
use of high dose IVC in cancer patients. High-dose intravenous
vitamin C (IVC) has been used for decades as a complementary,
alternative, and adjuvant medicine in clinic, and has been shown
to significantly prolong the survival of patients (Hoffer et al.,
2015). Although IVC has been clinically accepted and used
for many years, there are still many questions regarding the
clinical use of IVC in cancer therapy, such as the frequency and
duration of IVC treatment, the optimal route of medication,
safety, interaction with chemotherapy, quality of life, and the
potential mechanisms of action. Parent et al. examined the
relationship between dietary intake of vitamin C, in foods,
supplements and multivitamins, and the incidence of prostate
cancer in a large population-based case-control study, specifically
addressing the issues of cancer aggressiveness and screening
patterns. Their study included 1,916 histologically confirmed
prostate cancer cases and 1,985 population controls, information
on a wide range of socio-demographic, lifestyle, and medical
factors, including PSA screening. Consumption of 63 food items
2 years prior to diagnosis/interview was also collected, along with
the use of dietary supplements. Using the Prostate Cancer and
Environment Study (PROtEuS) in Montreal, Canada, their work
demonstrated that vitamin C did not seem to hold promise with
regard to prostate cancer prevention.
A combination of nutrition, nutraceuticals, and drugs is the
preferred therapeutic approach to fight against cancer. Colorectal
cancer (CRC) is classified a fatal type of cancer, and conventional
first and second line chemotherapeutic regimens for CRC are
based on a combination of drugs including fluoropyrimidine,
oxaliplatin (Oxa), and irinotecan (Iri). Pires et al. analyzed the
combination of high concentrations of vitamin C with reduced
concentrations of drugs conventionally used in CRC patients and
found that pharmacological vitamin C increased the efficacy of
Iri and Oxa against CRC.
Another important part of this research topic is to discuss
vitamin C in the treatment of infectious diseases. It is well-known
that Gram-negative bacteria Helicobacter pylori are closely
related to stomach diseases and gastric cancer. A large number of
clinical reports have shown that ascorbate deficiency is associated
with gastritis. In patients with H. pylori-infected gastritis, H.
pylori, first discovered by Robin Warren and Barry Marshall, is
one of the most common bacterial infections in gastritis, with
H. pylori infection exceeding 50%. Gastritis and peptic ulcers are
also caused by infectious pathogens that eventually develop into
chronic gastritis, mucosa-associated lymphoma, and even gastric
adenocarcinoma. In this research topic, Mei and Tu summarizes
the relationship between vitamin C and H. pylori infection, and
outlines potential strategies to prevent H.pylori infection that are
based on emerging advances in our understanding of ascorbic
acid physiology and pharmacology.
The final chapter in this research topic brings together a
number of related dermatological studies which have shown
that vitamin C can effectively promote the formation of
the skin barrier via collagen synthesis, establishing a natural
antioxidant barrier in the dermis, and regulating skin cell
growth, differentiation, and signal transduction. Severe vitamin C
deficiency leads to atopic dermatitis (AD) and porphyria (PCT).
Vitamin C can be an effective drug for treating skin diseases,
but the appropriate doses require further study. In this research
topic, Wang et al. summarize the effects of vitamin C on five skin
diseases (porphyria cutanea tarda, atopic dermatitis, malignant
melanoma, and herpes zoster and postherpetic neuralgia) and
emphasize the clinical application of vitamin C as an adjuvant
for drugs or physical therapy for other skin diseases.
Together, this research topic gives insight into the multiple
and complex roles of vitamin C, and in particular its involvement
in cancer and infectious diseases. It provides guidance for
therapeutic approaches and future research on the clinical use
of high-dose intravenous vitamin C. Through research we need
to better understand the mechanisms of vitamin C action,
the optimal administration route, the appropriate dose and
administration frequency. From such work we will gain insights
into the clinical value of vitamin C, its role at a physiological
and biochemical level, and expand the value of vitamin C in the
treatment of cancer and infectious diseases. We look forward to
new applied and useful data in this growing area.
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